Non-IgG Antibody Products and Services at Creative Biolabs to Forward Vaccine Development
During the COVID-19 outbreak, researchers have found that IgA antibodies dominated the early response to SARS-CoV-2, coming faster and more strongly than IgG and IgM antibodies. The results of this study may provide insights into the development of vaccines that trigger IgA responses and the development of IgA-based tests to detect early-stage infections. This also puts non-IgG antibodies, such as IgA, back in the spotlight, emphasizing the important role they may play in biotechnology and human healthcare.
As scientists are paying more and more attention to developing novel vaccines which take full advantage of non-IgG antibodies, Creative Biolabs now announces to offering one-stop non-IgG antibody products and services for vaccine development services based on the professional antibody platforms and vaccine platform.
The scientist team highlights secretory IgA (sIgA) playing a key role in regulating infection caused by viruses or bacteria, showing great potential in vaccine development. Creative Biolabs offers a wide range of premade IgA monoclonal and polyclonal antibodies with high purity and quality. Furthermore, a panel of IgA-based vaccine development services is also available, including mucosal vaccine development targeting various cells, new vaccine adjuvant selection for induction of S-IgA, the improvement of vaccine delivery systems for S-IgA inducing vaccines, and the immunogenicity and safety evaluation of vaccine.
It’s proved that IgM can block HIV transmission and delay the progression of the disease in vivo, thus being widely used in anti-HIV vaccine development. The scientists at Creative Biolabs have designed IgM antibodies of different species for vaccine development projects, and are fully equipped to provide IgM vaccine development services, such as live attenuated and virus-like particles vaccine design, vaccine target validation, development of vaccine delivery system, the immunogenicity and safety evaluation of vaccine, and cell-based vaccine development.
Besides, IgE antibody is also a focus of Creative Biolabs with custom or premade IgE antibodies for vaccine development. IgE antibody-based vaccine development services cover the whole process from vaccine design to immunogenicity and safety evaluation.
“We know that what researchers do every day is challenging, so we aspire to be a company that is easy for clients to work with. With more and more research focusing on non-IgG antibodies’ application for vaccine development, we are dedicated to updating our non-IgG therapeutic antibody platform to serve great products and services, supporting the pursuit of a healthier world,” said a scientist at Creative Biolabs.
More information can be found on the official website: https://non-igg-ab.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and years of experience in biomedical science, Creative Biolabs is skilled at providing non-IgG antibody development services with the support of the cutting-edge Antibody GlycoOpitimize Platform and Expression System Platform. High-quality off-the-shelf non-IgG products (mainly IgA, IgM, and IgE monoclonal/polyclonal antibodies) and non-IgG antibody ELISA kits are also available for both academic and commercial usage.